Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Smith-and-Nephew stock

Own Smith-and-Nephew stock in just a few minutes.

Smith & Nephew plc is a medical devices business based in the US. Smith-and-Nephew shares (SNN) are listed on the NYSE and all prices are listed in US Dollars. Smith-and-Nephew employs 17,914 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Smith-and-Nephew

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – SNN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Smith-and-Nephew share price

Use our graph to track the performance of SNN stocks over time.

Smith-and-Nephew shares at a glance

Information last updated 2021-04-23.
52-week range$33.87 - $45.54
50-day moving average $38.58
200-day moving average $40.29
Wall St. target price$49.50
PE ratio 40.4248
Dividend yield $0.375 (0.91%)
Earnings per share (TTM) $1.02

Buy Smith-and-Nephew shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Currencies
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
$0
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
$0
Stocks, ETFs
N/A
$0 per month
N/A
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Smith-and-Nephew stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Is Smith-and-Nephew under- or over-valued?

Valuing Smith-and-Nephew stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Smith-and-Nephew's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Smith-and-Nephew's P/E ratio

Smith-and-Nephew's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Smith-and-Nephew shares trade at around 40x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Smith-and-Nephew's PEG ratio

Smith-and-Nephew's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.8725. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Smith-and-Nephew's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Smith-and-Nephew's EBITDA

Smith-and-Nephew's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $883 million.

The EBITDA is a measure of a Smith-and-Nephew's overall financial performance and is widely used to measure a its profitability.

Smith-and-Nephew financials

Revenue TTM $4.6 billion
Operating margin TTM 9.5%
Gross profit TTM $3.2 billion
Return on assets TTM 2.67%
Return on equity TTM 8.6%
Profit margin 9.83%
Book value $12.06
Market capitalisation $18.1 billion

TTM: trailing 12 months

Shorting Smith-and-Nephew shares

There are currently 1.1 million Smith-and-Nephew shares held short by investors – that's known as Smith-and-Nephew's "short interest". This figure is 24.4% down from 1.5 million last month.

There are a few different ways that this level of interest in shorting Smith-and-Nephew shares can be evaluated.

Smith-and-Nephew's "short interest ratio" (SIR)

Smith-and-Nephew's "short interest ratio" (SIR) is the quantity of Smith-and-Nephew shares currently shorted divided by the average quantity of Smith-and-Nephew shares traded daily (recently around 448450.19920319). Smith-and-Nephew's SIR currently stands at 2.51. In other words for every 100,000 Smith-and-Nephew shares traded daily on the market, roughly 2510 shares are currently held short.

However Smith-and-Nephew's short interest can also be evaluated against the total number of Smith-and-Nephew shares, or, against the total number of tradable Smith-and-Nephew shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Smith-and-Nephew's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Smith-and-Nephew shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Smith-and-Nephew shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Smith-and-Nephew.

Find out more about how you can short Smith-and-Nephew stock.

Smith-and-Nephew share dividends

2%

Dividend payout ratio: 1.66% of net profits

Recently Smith-and-Nephew has paid out, on average, around 1.66% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.82% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Smith-and-Nephew shareholders could enjoy a 1.82% return on their shares, in the form of dividend payments. In Smith-and-Nephew's case, that would currently equate to about $0.375 per share.

While Smith-and-Nephew's payout ratio might seem low, this can signify that Smith-and-Nephew is investing more in its future growth.

Smith-and-Nephew's most recent dividend payout was on 11 May 2021. The latest dividend was paid out to all shareholders who bought their shares by 4 April 2021 (the "ex-dividend date").

Have Smith-and-Nephew's shares ever split?

Smith-and-Nephew's shares were split on a 2499:1000 basis on 14 October 2014. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 2499 shares. This wouldn't directly have changed the overall worth of your Smith-and-Nephew shares – just the quantity. However, indirectly, the new 60% lower share price could have impacted the market appetite for Smith-and-Nephew shares which in turn could have impacted Smith-and-Nephew's share price.

Smith-and-Nephew share price volatility

Over the last 12 months, Smith-and-Nephew's shares have ranged in value from as little as $33.8735 up to $45.5399. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Smith-and-Nephew's is 0.3882. This would suggest that Smith-and-Nephew's shares are less volatile than average (for this exchange).

Smith-and-Nephew overview

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site